-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The New Year is approaching, and the profit-making effect of the pharmaceutical and medical sector continues to spread
.
For example, the three pharmaceutical stocks of the Beijing Stock Exchange, Senxuan Pharmaceutical, Datang Pharmaceutical, and Lude Medical, have even experienced a "30cm" daily limit
.
Among them, Senxuan Pharmaceutical closed two daily limit prices in a row on December 29 and December 30, and the yield on the 5th was as high as 148%
.
It is understood that Senxuan Pharmaceuticals, a stock on the Beijing Stock Exchange, has a daily limit of 30cm for two consecutive days, becoming the first stock on the Beijing Stock Exchange with a continuous daily limit, and the company's shareholder, Essence Pharmaceuticals, on the Shenzhen main board, has staged six daily daily limits in 7 days
.
After the skyrocketing, Senxuan Pharmaceutical's new closing price was 18.
83 yuan, with a total market value of 8 billion yuan
.
According to the data, Senxuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemical raw materials, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates, of which the raw materials mainly cover anti-tumor raw materials, antipyretic, analgesic and anti-inflammatory raw materials.
Pharmaceuticals, anti-epileptic APIs, etc.
; pharmaceutical intermediates mainly include anti-AIDS pharmaceutical intermediates, anti-epileptic pharmaceutical intermediates, anti-tumor pharmaceutical intermediates, etc.
; oxygen-containing heterocyclic chemical intermediates mainly include dioxopenta ring, dioxane
.
It is understood that Senxuan Pharmaceutical is an API subsidiary of Essence Pharma, an A-share listed company, and Essence Pharma holds a 72.
31% stake in the company
.
To a certain extent, the rise of Senxuan Pharmaceutical is also related to the hot trend of the parent company in A shares
.
Essence Pharma once said in answering questions from investors: "The annual production capacity of the main intermediates of ritonavir, a subsidiary of the company, Senxuan Pharmaceuticals is about 30 tons.
According to the preliminary investigation and statistics of Senxuan Pharmaceuticals, the current market share of such intermediates is about 70%.
"
Senxuan Pharmaceutical said that the company's current products of ritonavir series intermediates are mainly used in the synthesis of anti-AIDS ritonavir APIs
.
On the evening of December 30, Senxuan Pharmaceutical issued an announcement to clarify that it did not have a purchase and sales cooperation with Pfizer
.
The company issued an announcement on the evening of the 30th to remind investors that the company has not signed a contract for the purchase and sale of ritonavir pharmaceutical intermediates with Pfizer.
Investors are requested to invest rationally and pay attention to risks
.
It is reported that Senxuan Pharmaceutical has a rich product structure.
At present, there are 19 kinds of API products, 3 kinds of pharmaceutical intermediate products and 2 kinds of chemical intermediate products, covering anti-tumor, antipyretic, analgesic and anti-inflammatory, anti-hyperthyroidism, Antiepileptic, antibacterial, antihypertensive, antiplatelet aggregation, cardiovascular treatment, hepatitis treatment, malaria treatment, Parkinson's treatment and many other fields
.
The data shows that from 2018 to 2020, Senxuan Pharmaceutical’s performance has maintained steady growth, with revenue of 385 million yuan, 507 million yuan, and 545 million yuan, respectively, and net profit attributable to the parent of 46.
86 million yuan, 106 million yuan, and 144 million yuan, respectively
.
In the first three quarters of 2021, the company achieved revenue of 398 million yuan; net profit attributable to the parent was 98 million yuan
.
At the same time, Senxuan Pharmaceutical's R&D investment has also increased in recent years
.
Among them, from 2018 to 2020, Senxuan Pharmaceutical's investment in research and development was 17.
8 million yuan, 21.
76 million yuan, and 25.
25 million yuan respectively
.
Regarding the future, Senxuan Pharmaceutical stated that it has planned four development directions: making refined raw materials, making specialized intermediates, making new materials, and deploying generic drugs and innovative drugs
.
.
For example, the three pharmaceutical stocks of the Beijing Stock Exchange, Senxuan Pharmaceutical, Datang Pharmaceutical, and Lude Medical, have even experienced a "30cm" daily limit
.
Among them, Senxuan Pharmaceutical closed two daily limit prices in a row on December 29 and December 30, and the yield on the 5th was as high as 148%
.
It is understood that Senxuan Pharmaceuticals, a stock on the Beijing Stock Exchange, has a daily limit of 30cm for two consecutive days, becoming the first stock on the Beijing Stock Exchange with a continuous daily limit, and the company's shareholder, Essence Pharmaceuticals, on the Shenzhen main board, has staged six daily daily limits in 7 days
.
After the skyrocketing, Senxuan Pharmaceutical's new closing price was 18.
83 yuan, with a total market value of 8 billion yuan
.
According to the data, Senxuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemical raw materials, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates, of which the raw materials mainly cover anti-tumor raw materials, antipyretic, analgesic and anti-inflammatory raw materials.
Pharmaceuticals, anti-epileptic APIs, etc.
; pharmaceutical intermediates mainly include anti-AIDS pharmaceutical intermediates, anti-epileptic pharmaceutical intermediates, anti-tumor pharmaceutical intermediates, etc.
; oxygen-containing heterocyclic chemical intermediates mainly include dioxopenta ring, dioxane
.
It is understood that Senxuan Pharmaceutical is an API subsidiary of Essence Pharma, an A-share listed company, and Essence Pharma holds a 72.
31% stake in the company
.
To a certain extent, the rise of Senxuan Pharmaceutical is also related to the hot trend of the parent company in A shares
.
Essence Pharma once said in answering questions from investors: "The annual production capacity of the main intermediates of ritonavir, a subsidiary of the company, Senxuan Pharmaceuticals is about 30 tons.
According to the preliminary investigation and statistics of Senxuan Pharmaceuticals, the current market share of such intermediates is about 70%.
"
Senxuan Pharmaceutical said that the company's current products of ritonavir series intermediates are mainly used in the synthesis of anti-AIDS ritonavir APIs
.
On the evening of December 30, Senxuan Pharmaceutical issued an announcement to clarify that it did not have a purchase and sales cooperation with Pfizer
.
The company issued an announcement on the evening of the 30th to remind investors that the company has not signed a contract for the purchase and sale of ritonavir pharmaceutical intermediates with Pfizer.
Investors are requested to invest rationally and pay attention to risks
.
It is reported that Senxuan Pharmaceutical has a rich product structure.
At present, there are 19 kinds of API products, 3 kinds of pharmaceutical intermediate products and 2 kinds of chemical intermediate products, covering anti-tumor, antipyretic, analgesic and anti-inflammatory, anti-hyperthyroidism, Antiepileptic, antibacterial, antihypertensive, antiplatelet aggregation, cardiovascular treatment, hepatitis treatment, malaria treatment, Parkinson's treatment and many other fields
.
The data shows that from 2018 to 2020, Senxuan Pharmaceutical’s performance has maintained steady growth, with revenue of 385 million yuan, 507 million yuan, and 545 million yuan, respectively, and net profit attributable to the parent of 46.
86 million yuan, 106 million yuan, and 144 million yuan, respectively
.
In the first three quarters of 2021, the company achieved revenue of 398 million yuan; net profit attributable to the parent was 98 million yuan
.
At the same time, Senxuan Pharmaceutical's R&D investment has also increased in recent years
.
Among them, from 2018 to 2020, Senxuan Pharmaceutical's investment in research and development was 17.
8 million yuan, 21.
76 million yuan, and 25.
25 million yuan respectively
.
Regarding the future, Senxuan Pharmaceutical stated that it has planned four development directions: making refined raw materials, making specialized intermediates, making new materials, and deploying generic drugs and innovative drugs
.
